Journal for ImmunoTherapy of Cancer,
Journal Year:
2025,
Volume and Issue:
13(1), P. e008876 - e008876
Published: Jan. 1, 2025
Cancer
immunotherapy-including
immune
checkpoint
inhibition
(ICI)
and
adoptive
cell
therapy
(ACT)-has
become
a
standard,
potentially
curative
treatment
for
subset
of
advanced
solid
liquid
tumors.
However,
most
patients
with
cancer
do
not
benefit
from
the
rapidly
evolving
improvements
in
understanding
principal
mechanisms
determining
responsiveness
(CIR);
including
patient-specific
genetically
determined
acquired
factors,
as
well
intrinsic
biology.
Though
CIR
is
multifactorial,
fundamental
concepts
are
emerging
that
should
be
considered
design
novel
therapeutic
strategies
related
clinical
studies.
Recent
advancements
approaches
to
address
limitations
current
treatments
discussed
here,
specific
focus
on
ICI
ACT.
Nature,
Journal Year:
2022,
Volume and Issue:
611(7934), P. 155 - 160
Published: Oct. 26, 2022
Abstract
Relatlimab
and
nivolumab
combination
immunotherapy
improves
progression-free
survival
over
monotherapy
in
patients
with
unresectable
advanced
melanoma
1
.
We
investigated
this
regimen
resectable
clinical
stage
III
or
oligometastatic
IV
(NCT02519322).
Patients
received
two
neoadjuvant
doses
(nivolumab
480
mg
relatlimab
160
intravenously
every
4
weeks)
followed
by
surgery,
then
ten
of
adjuvant
therapy.
The
primary
end
point
was
pathologic
complete
response
(pCR)
rate
2
resulted
57%
pCR
70%
overall
among
30
treated.
radiographic
using
Response
Evaluation
Criteria
Solid
Tumors
1.1
57%.
No
grade
3–4
immune-related
adverse
events
were
observed
the
setting.
1-
2-year
recurrence-free
100%
92%
for
any
response,
compared
to
88%
55%
who
did
not
have
a
(
P
=
0.005).
Increased
immune
cell
infiltration
at
baseline,
decrease
M2
macrophages
during
treatment,
associated
response.
Our
results
indicate
that
induces
high
rate.
Safety
therapy
is
favourable
other
regimens.
These
data,
RELATIVITY-047
trial
,
provide
further
confirmation
efficacy
safety
new
regimen.
